A Clinical Trial Investigating the Effect of Salmon Bone Meal on Bone Mass Among Osteopenic Women

NCT ID: NCT05066477

Last Updated: 2025-09-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-09-22
• Study Completion Date: 2025-06-12

Brief Summary

The purpose of this study is to evaluate the efficacy of salmon bone meal in preventing bone loss among perimenopausal women with reduced bone mass density.

Detailed Description

The current study is part of a larger project called the CalGo-project. The overall purpose of the study is to use bone meal from salmon to promote skeletal health. Specifically, the effect of salmon bone meal on bone mass density among perimenopausal women (age ≥ 50 years) with osteopenia is investigated over a time period of 2 years. Salmon bone meal is composed of a natural microcrystalline hydroxyapatite form of calcium and phosphorus, collagen type 2. Past literature on mammalian sources of bone meal has indicated that this form of calcium is superior in terms of preserving bone mass density compared to traditional calcium supplements. Preserving bone mass is essential to reduce the risk of future fragility fractures. Osteopenia is a condition of reduced bone mass density and bone quality which can indicate the later onset of clinical osteoporosis. Both are conditions associated with a significant risk of fragility fractures, which are a major global health burden.

Bone mass density is measured using dual-energy X-ray absorptiometry. Markers of bone formation P1NP and CTX-1 will be measured in serum samples of participants. 100 potential participants will be screened for eligibility. Participants who meet the eligibility criteria will be randomized in a double-blind manner to receive 4 capsules daily of salmon bone meal enriched with Vitamin D3 per capsule.

Conditions

Osteopenia; Osteopenia of the Elderly

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: TRIPLE

Study Groups

CalGo (Salmon bone meal)

4 capsules daily of CalGo (salmon bone meal enriched with Vitamin D3) is taken per orally. Each capsule contains \~500 mg of salmon bone meal (380 mg calcium, 200 mg phosphorus, 500 mg native collagen type 2), and 10 micrograms of vitamin D3 (400 IU). Once daily dosing. Duration: 2 years.

Group Type: ACTIVE_COMPARATOR

CalGo

Intervention Type: DIETARY_SUPPLEMENT

CalGo is a natural marine collagenic bone powder from salmon. The bone powder is a 100 % microcrystalline hydroxyapatite form of calcium and phosphorus. Furthermore it contains collagen type 2 and is enriched with vitamin D3.

Maltodextrin

4 capsules daily of maltodextrin is taken per orally. Each capsule contains 500 mg of maltodextrin. Once daily dosing. Duration: 2 years.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Pure maltodextrin

Interventions

CalGo

CalGo is a natural marine collagenic bone powder from salmon. The bone powder is a 100 % microcrystalline hydroxyapatite form of calcium and phosphorus. Furthermore it contains collagen type 2 and is enriched with vitamin D3.

Intervention Type: DIETARY_SUPPLEMENT

Placebo

Pure maltodextrin

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Female gender
• ≥ 50 years of age
• DXA T-score of > -2.5 standard deviations, but ≤ -1 (osteopenic range)
• Steady state body weight 1 month before study commencement date
• No contraindications for intake of the interventional product, including a prior diagnosis of fish allergy.
• Familiar with the Norwegian language, both in writing and orally

Exclusion Criteria

• A diagnosis of osteoporosis (BMD T-score ≤ -2.5 SD as diagnosed by DXA), or any previously diagnosed fragility fractures on a background of osteoporosis.
• Use of drugs known to affect bone metabolism, including:

• Glucocorticoids
• Thyroid hormones
• Hormone replacement therapy taken continuously for a duration of less than 6 months.
• Long-term heparin therapy
• Anti-convulsive drugs
• Long-term proton pump inhibitor treatment
• Lithium
• Anti-osteoporotic drugs
• Cancer therapy
• Selective estrogen receptor modulators.
• Any disease or medical condition known to affect bone tissue, including neoplasia with or without metastasis, Paget's disease of bone, Osteomalacia, or any other disease deemed relevant by the PI.
• Gastrointestinal diseases or disturbances potentially affecting absorption of nutrients, including Crohn's disease and Celiac disease.
• Hypersensitivity to ingredients in the interventional product, including fish allergy.
• Not willing to participate in the study.
• Other reasons that the PI deems it necessary to exclude the subject.

• Minimum Eligible Age: 50 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Møre og Romsdal Hospital Trust

OTHER

Sponsor Role: collaborator

Hofseth Biocare ASA

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Øystein B Lian, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Møre og Romsdal Hospital Trust (Helse Møre og Romsdal), Kristiansund Hospital

Locations

Hofseth Biocare ASA

Ålesund, Møre og Romsdal, Norway

Kristiansund Hospital

Kristiansund, Møre og Romsdal, Norway

Lovisenberg Diakonale Sykehus

Oslo, , Norway

Countries

Norway

Other Identifiers

CALGO-OST

Identifier Type: -

Identifier Source: org_study_id